Biocept (BIOC) Stock Forecast, Price & News

Biocept (NASDAQ:BIOC) Frequently Asked Questions

Is Biocept a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept or view top-rated stocks.

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Wednesday, May 25th 2022.
View our earnings forecast for Biocept.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings results on Tuesday, April, 5th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Biocept had a negative trailing twelve-month return on equity of 5.35% and a negative net margin of 2.89%. During the same quarter in the previous year, the business posted $0.14 earnings per share.
View Biocept's earnings history.

When did Biocept's stock split? How did Biocept's stock split work?

Biocept's stock reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

Who are Biocept's key executives?

Biocept's management team includes the following people:

• Mr. Samuel D. Riccitelli, Interim Pres, CEO & Chairman (Age 63)
• Mr. Michael Terry, Sr. VP of Corp. Devel. (Age 67, Pay $306.47k)
• Dr. Soon Kap Hahn Ph.D., Founder
• Mr. Antonino Morales, Interim CFO & Director (Age 66)
• Dr. Philippe J. Marchand Ph.D., Chief Operating Officer (Age 59)
• Mr. Pavel Tsinberg, Director of Technology Devel.
• Mr. Darrell Taylor Esq., Sr. VP, Chief Legal Officer & Chief Compliance Officer
• Mr. David S. Moskowitz R.Ph., MBA, VP of Strategy & Corp. Communications
• Antonio Paternostro, VP of Sales
• Dr. Veena M. Singh, Sr. Medical Director (Age 47)

What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Biocept's key competitors?

Some companies that are related to Biocept include Celcuity (CELC), Exagen (XGN), Sera Prognostics (SERA), Psychemedics (PMD), Vyant Bio (VYNT), PharmChem (PCHM), OpGen (OPGN), CannLabs (CANL), Aclarion (ACON), American Shared Hospital Services (AMS), CBA Florida (CBAI), AnPac Bio-Medical Science (ANPC), Zicix (ZICX), PotNetwork (POTN) and ACI Global (ACGJ).
View all of BIOC's competitors.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.69%), Acadian Asset Management LLC (0.16%), Taylor & Morgan Wealth Management LLC (0.14%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Biocept stock include David F Hale and David F Hale.
View institutional ownership trends for Biocept.

Which institutional investors are selling Biocept stock?

BIOC stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC.
View insider buying and selling activity for Biocept or view top insider-selling stocks.

Which institutional investors are buying Biocept stock?

BIOC stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Taylor & Morgan Wealth Management LLC, and Group One Trading L.P..
View insider buying and selling activity for Biocept or or view top insider-buying stocks.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $1.44.

How much money does Biocept make?

Biocept has a market capitalization of $24.34 million and generates $61.25 million in revenue each year. The medical research company earns $-2.82 million in net income (profit) each year or ($0.100010) on an earnings per share basis.

How many employees does Biocept have?

Biocept employs 104 workers across the globe.

What is Biocept's official website?

The official website for Biocept is www.biocept.com.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225.